Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31115536 | 0.98 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| SCHEMBL19646456 | 0.98 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| SCHEMBL16328702 | 0.98 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| SCHEMBL6860661 | 0.98 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| SCHEMBL12501215 | 0.94 | ALOX12 (0.53) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| SCHEMBL22891256 | 0.88 | FAAH (0.53) | ALOX12FAAHMGLL | |
| SCHEMBL6478495 | 0.87 | ALOX12 (0.45) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| Triethylene Glycol SCHEMBL6478490 | 0.85 | KMT2A (0.56) | ALOX12LMNASMN1; SMN2HPGDMAPT | |
| SCHEMBL4587864 | 0.85 | ALOX12 (0.47) | ALOX12LMNASMN1; SMN2HPGDTDP1 | |
| SCHEMBL27847323 | 0.82 | ALOX12 (0.47) | ALOX12LMNASMN1; SMN2HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0549665-A1 | POLY(FLUOROALKYL) SUGAR REAGENTS AND THEIR USE FOR SURFACE MODIFICATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-07-07 | — | — | EP | claimed |
| WO-1992005445-A1 | POLY(FLUOROALKYL) SUGAR REAGENTS AND THEIR USE FOR SURFACE MODIFICATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-02 | — | — | WO | claimed |
| US-11027043-B1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-106669822-B | A kind of preparation method of composite bionic mineralising nano biological catalyst | 河北工业大学 | 2019-11-05 | — | — | CN | disclosed |
| CN-106669822-A | Preparation method of compound biomimetic mineralization nano biocatalyst | 河北工业大学 | 2017-05-17 | — | — | CN | disclosed |
| US-20170049924-A1 | CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES | HYPERBRANCH MEDICAL TECHNOLOGY, INC. | 2017-02-23 | — | — | US | disclosed |
| CN-105960406-A | Triazine mediated living radical controlled polymerization | 陶氏环球技术有限责任公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-102307562-A | Methods and compositions for treating P.acnes | UNIV CALIFORNIA | 2012-01-04 | — | — | CN | disclosed |
| US-4113632-A | ALIPHATIC SUBSTITUTED SUCCINIMIDO ARYL HYDROXY SULFONATE OR ITS SUCCINAMIC ACID DERIVATIVE | MOBIL OIL CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11027043-B1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | ALOX12 2435/4885LMNA 779/4885SMN1; SMN2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.